Welcome to our dedicated page for CoreWeave SEC filings (Ticker: CRWV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CoreWeave, Inc. filings document the regulatory record for an AI cloud infrastructure company listed on Nasdaq with Class A common stock. The company’s 8-K reports cover operating results, customer cloud-capacity agreements, private placements of equity securities, senior notes, credit facilities, and related guarantees or collateral arrangements.
Proxy materials disclose annual meeting matters, stockholder voting items, board governance, executive compensation, and equity-award information. Capital-structure filings describe senior unsecured notes due 2031, subsidiary guarantees, private placement registration rights, and debt facilities used to finance GPU servers and related infrastructure for customer contracts.
CoreWeave, Inc. disclosed that Principal Accounting Officer Jeff Baker received a grant of 21,433 restricted stock units on February 10, 2026. Each unit represents a contingent right to receive one share of CoreWeave Class A common stock upon settlement.
The award will vest in equal installments of 1/16 of the total grant on the 20th calendar day of May, August, November, and February, with the first tranche vesting on May 20, 2026, so long as Baker continues serving the company on each vesting date. The RSUs do not have a set expiration date and will either vest on schedule or be cancelled before vesting.
CoreWeave, Inc.’s Chief Financial Officer, Nitin Agrawal, reported an equity award of 128,603 restricted stock units (RSUs) granted on February 10, 2026. Each RSU represents a contingent right to receive one share of CoreWeave’s Class A common stock upon settlement.
The award vests in equal installments, with 1/16 of the total RSUs vesting on the 20th calendar day of May, August, November, and February, assuming Agrawal continues to serve the company on each vesting date. The first tranche is scheduled to vest on May 20, 2026, and the RSUs either vest or are cancelled before vesting; they do not have a traditional expiration date.
CoreWeave, Inc.’s Chief Development Officer McBee Brannin reported indirect transactions in family trusts holding company stock. On February 9, 2026, the Canis Major 2025 GRAT converted 25,000 shares of Class B Common Stock into the same number of Class A shares, and the Canis Minor 2025 GRAT converted 8,335 Class B shares into Class A.
Both GRATs then executed a series of open‑market sales of Class A Common Stock under a Rule 10b5‑1 trading plan adopted on November 17, 2025, at weighted average prices generally in the high‑$80s to high‑$90s per share. These sales reduced the Class A holdings of each GRAT reported in this part of the filing to zero.
The filing also notes additional indirect holdings: Class B Common Stock held by Brannin’s spouse and Class A Common Stock held by a child, reflecting broader family ownership in CoreWeave shares.
CoreWeave, Inc.’s Chief Development Officer, McBee Brannin, reported trust-level share conversions and sales on February 9, 2026. Trusts associated with Brannin converted Class B Common Stock into Class A Common Stock, then sold small blocks of Class A shares in multiple transactions.
The Canis Major 2024 Irrevocable Trust LLC, Canis Major 2025 Family Trust LLC, and Canis Minor 2025 Family Trust LLC executed the trades. Sales of Class A shares occurred at prices ranging from about $89.76 to $97.35 per share under a Rule 10b5-1 trading plan adopted on November 17, 2025.
CoreWeave, Inc.’s Chief Development Officer Brannin McBee reported converting 102,830 shares of Class B Common Stock into Class A directly, and 25,000 Class B shares held by the Brannin J. McBee 2022 Irrevocable Trust into Class A.
Following these conversions, McBee and two family trusts reported multiple open‑market sales of Class A shares under a Rule 10b5‑1 trading plan adopted on November 17, 2025, at weighted average prices within ranges from $89.09 to $97.85 per share. After these transactions, McBee beneficially owned 248,664 Class A shares directly, 54,500 Class A shares through the Canis Major Trust, and 8,294,490 Class B shares directly, plus 3,991,020 Class B shares through the 2022 Irrevocable Trust.
CRWV insider has filed a Rule 144 notice to sell up to 50,000 common shares through Morgan Stanley Smith Barney LLC on or about 02/11/2026 on NASDAQ, with an aggregate market value of $4,755,500.
The shares are founder shares acquired from the issuer on 11/13/2017. The filing also lists multiple recent Rule 10b5-1 common stock sales by Michael Intrator, Omnadora Capital LLC, and a non‑affiliate donee over the prior three months, with individual transactions ranging from 32,455 to 78,971 shares.
CRWV insider activity shows a planned Rule 144 sale of 32,455 shares of common stock through Morgan Stanley Smith Barney, with an aggregate market value of $3,086,795.05, on or about February 11, 2026 on NASDAQ.
The seller acquired these 32,455 shares as founder shares on November 13, 2017. Recent activity also includes multiple 10b5-1 plan sales by Michael Intrator and Omnadora Capital LLC over the prior three months, each involving blocks of common stock with multi‑million dollar gross proceeds.
A Form 144 filing for CRWV reports a planned sale of 500 shares of common stock with an aggregate market value of 44975.00. The shares, described as Founders Shares, were acquired from the issuer on 02/25/2019 and will be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with 386401201 shares of common stock outstanding.
The notice also lists extensive recent Rule 10b5-1 sales of CRWV common stock from 12/01/2025 through 02/02/2026 by Brannin McBee, related trusts and LLCs, and a non-affiliate donee, covering multiple block transactions and multi-million-dollar gross proceeds.
CRWV filed a notice that a shareholder plans to sell 102,830 common shares, with an aggregate market value of 9249558.50, through Morgan Stanley Smith Barney on 02/09/2026 on NASDAQ. The filing notes 386,401,201 common shares outstanding. The shares were originally acquired as founder shares on 02/25/2019.
The notice also lists extensive recent Rule 10b5-1 sales of CRWV common stock over the past three months by Brannin McBee, related trusts and entities, and a non-affiliate donee, including individual trades such as 102,835 shares for 9799589.34 and 257,733 shares for 19592527.61.
CRWV received a Rule 144 notice for the planned sale of 3,000 common shares, with an aggregate market value of $269,850. These are founder shares acquired on February 25, 2019, to be sold through Morgan Stanley Smith Barney on the NASDAQ around February 9, 2026.
The filing notes that 386,401,201 common shares are outstanding. It also lists numerous recent 10b5-1 sales of CRWV common stock in late 2025 and early 2026 by Brannin McBee and various Canis Major/Canis Minor trusts, with individual transactions ranging from 500 shares to over 102,835 shares and gross proceeds in the millions of dollars.